Core Viewpoint - As of July 30, 2025, Hongbo Pharmaceutical (301230) experienced a decline of 3.52% in stock price, closing at 39.43 yuan, with significant net outflow of funds indicating potential investor concerns [1]. Financial Performance - For Q1 2025, the company reported total revenue of 169 million yuan, representing a year-on-year growth of 29.61% - Net profit attributable to shareholders reached 11.97 million yuan, showing a substantial increase of 226.47% - The non-recurring net profit was 9.68 million yuan, reflecting a remarkable growth of 1448.20% - The liquidity ratios were strong, with a current ratio of 4.359 and a quick ratio of 3.852, while the debt-to-asset ratio stood at 21.41% [1]. Company Background - Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. was established in 2007 and is located in Shanghai, focusing on research and experimental development - The company has a registered capital of approximately 139.59 million yuan and a paid-in capital of about 85.28 million yuan - The legal representative of the company is Ping Chen [1][2]. Investment and Intellectual Property - The company has made investments in 7 enterprises and participated in 5 bidding projects - It holds 6 trademark registrations and 40 patents, along with 44 administrative licenses [2].
泓博医药（301230）7月30日主力资金净流出5022.36万元